ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today provided a corporate update for the second quarter of 2017, including key accomplishments, a status update on ongoing programs, and the Company’s outlook for near-term value creation.
A narrated corporate overview of second quarter 2017 progress and outlook for the future is available on the ProMIS Neurosciences website at: http://bit.ly/2tRLGAI .
Key accomplishments in the second quarter of 2017 and near-term value drivers include:
· Expansion of potential best in class amyloid-beta (AB) portfolio for Alzheimer’s disease
· Designated PMN350 as second validated product lead; in vivo data and biologic evidence of neuronal protection against toxic AB oligomers